Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(3.32)
# 663
Out of 5,182 analysts
49
Total ratings
40.48%
Success rate
24.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GENB Generate Biomedicines | Initiates: Overweight | n/a | $12.45 | - | 1 | Mar 24, 2026 | |
| LEGN Legend Biotech | Maintains: Overweight | $75 → $74 | $23.65 | +212.90% | 3 | Dec 17, 2025 | |
| VSTM Verastem | Assumes: Overweight | n/a | $5.54 | - | 1 | Oct 16, 2025 | |
| ACLX Arcellx | Assumes: Neutral | $88 | $115.07 | -23.52% | 1 | Oct 9, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $22.12 | - | 3 | Sep 8, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Overweight | n/a | $46.29 | - | 1 | Jul 17, 2025 | |
| PRTA Prothena Corporation | Reiterates: Neutral | n/a | $10.79 | - | 2 | Jun 20, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $11.35 | - | 4 | Apr 1, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $24.75 | - | 4 | Mar 20, 2025 | |
| BCAX Bicara Therapeutics | Reiterates: Overweight | $13 | $22.48 | -42.11% | 2 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.76 | - | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $50.99 | - | 4 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $95.72 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $24.43 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $26.33 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $28.56 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $180.67 | +61.62% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $426.01 | -13.15% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.89 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.69 | - | 1 | May 30, 2017 |
Generate Biomedicines
Mar 24, 2026
Initiates: Overweight
Price Target: n/a
Current: $12.45
Upside: -
Legend Biotech
Dec 17, 2025
Maintains: Overweight
Price Target: $75 → $74
Current: $23.65
Upside: +212.90%
Verastem
Oct 16, 2025
Assumes: Overweight
Price Target: n/a
Current: $5.54
Upside: -
Arcellx
Oct 9, 2025
Assumes: Neutral
Price Target: $88
Current: $115.07
Upside: -23.52%
Summit Therapeutics
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $22.12
Upside: -
Scholar Rock Holding
Jul 17, 2025
Initiates: Overweight
Price Target: n/a
Current: $46.29
Upside: -
Prothena Corporation
Jun 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $10.79
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $11.35
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $24.75
Upside: -
Bicara Therapeutics
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $22.48
Upside: -42.11%
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.76
Upside: -
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $50.99
Upside: -
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $95.72
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $24.43
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $26.33
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $28.56
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $180.67
Upside: +61.62%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $426.01
Upside: -13.15%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.89
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $2.69
Upside: -